Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling
International Journal of Molecular Sciences · 01.04.2023 · 24 (7) · 6619
DOI: 10.3390/ijms24076619 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 01.04.2023. Verfasst von Hidenori Moriyama und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku 160-8582, Tokyo, Japan. Hauptthemen laut MEDLINE: Mast Cells, Airway Remodeling, Hypertension, Pulmonary, Pulmonary Artery. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 112 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Mast cells are responsible for IgE-dependent allergic responses, but they also produce various bioactive mediators and contribute to the pathogenesis of various cardiovascular diseases, including pulmonary hypertension (PH). The importance of lipid mediators in the pathogenesis of PH has become evident in recent years, as exemplified by prostaglandin I2, the most central therapeutic target in pulmonary arterial hypertension. New bioactive lipids other than eicosanoids have also been identified that are associated with the pathogenesis of PH. However, it remains largely unknown how mast cell-derived lipid mediators are involved in pulmonary vascular remodeling. Recently, it has been demonstrated that mast cells produce epoxidized n-3 fatty acid (n-3 epoxides) in a degranulation-independent manner, and that n-3 epoxides produced by mast cells regulate the abnormal activation of pulmonary fibroblasts and suppress the progression of pulmonary vascular remodeling. This review summarizes the role of mast cells and bioactive lipids in the pathogenesis of PH. In addition, we introduce the pathophysiological role and therapeutic potential of n-3 epoxides, a mast cell-derived novel lipid mediator, in the pulmonary vascular remodeling in PH. Further knowledge of mast cells and lipid mediators is expected to lead to the development of innovative therapies targeting pulmonary vascular remodeling.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku 160-8582, Tokyo, Japan.
- Department of Cardiology, Tokyo Dental College Ichikawa General Hospital, 5-11-13 Sugano, Ichikawa 272-8513, Chiba, Japan.
ORCID-Profile: Hidenori Moriyama, Jin Endo
Zitieren
APA
Moriyama, H., & Endo, J. (2023). Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling. International Journal of Molecular Sciences, 24(7), 6619. https://doi.org/10.3390/ijms24076619
Vancouver
Moriyama H, Endo J. Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling. International Journal of Molecular Sciences. 2023;24(7):6619. doi:10.3390/ijms24076619
BibTeX
@article{Moriyama2023,
author = {Moriyama, Hidenori and Endo, Jin},
title = {Pathophysiological Involvement of Mast Cells and the Lipid Mediators in Pulmonary Vascular Remodeling},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {7},
pages = {6619},
doi = {10.3390/ijms24076619}
}
EUVIMED